ACompany · Healthtech & Bio
Advanthera
Advanthera is a Spanish contract development and manufacturing organization (CDMO) offering a one-stop-shop of regulatory, clinical-trial supply, laboratory, and manufacturing services for advanced therapies (cell and gene therapies) across Europe. It was established as a strategic portfolio company of life-sciences VC firm Columbus Venture Partners, which added it to its portfolio in 2024. José Mesa, also a Partner at Columbus Venture Partners, is CEO.
Founded
2023
Founders
0
News
0
Rounds
0
Investors
1
SectorsAdvanced Therapies (Cell & Gene Therapy), CDMO / Biotech Manufacturing, Regulatory Affairs Services
Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO
Profile updated 20 Jul 2026
Founders
No names on record yet.
Global models 5
CCatalent
United States · www.catalent.com ↗
Major global CDMO offering manufacturing and development services for advanced/biologic therapies, similar end-to-end model to Advanthera though at much larger scale.
N/A (publicly listed, acquired by Novo Holdings for $16.5B in 2024)Comparable
RResilience (National Resilience)
United States · www.resilience.com ↗
VC-backed biomanufacturing platform for cell, gene and biologic therapies, matching Advanthera's manufacturing-for-hire model for advanced therapies.
$2.0BComparable
AAndelyn Biosciences
United States · www.andelynbio.com ↗
Gene-therapy focused CDMO providing manufacturing and development services, directly comparable to Advanthera's cell/gene therapy manufacturing focus.
$322MComparable
FForge Biologics
United States · www.forgebiologics.com ↗
Gene therapy CDMO offering process development, manufacturing and regulatory support, closely matching Advanthera's service scope.
$294MComparable
QQuell Therapeutics-adjacent CDMO peer: Cellares
United States · www.cellares.com ↗
Automated cell-therapy manufacturing platform serving biotech/pharma clients, aligning with Advanthera's advanced-therapy manufacturing services model.
$355MComparable
Investors 1
Funding rounds
No announced rounds on record.
News & media
No coverage on record yet.